Navigation Links
Singulex Closes $19 Million Financing Round
Date:1/12/2009

ALAMEDA, Calif., Jan. 12 /PRNewswire/ -- Singulex, Inc. today announced that it has closed a $19 million financing round, led by JAFCO Co., Ltd. and supported by existing investors including OrbiMed Advisors and Fisk Ventures. The financing round will support the commercialization of Singulex technologies in the diagnostics market. As part of the financing, Hironori Hozoji, investment officer for JAFCO Life Science Investment, will join the company's Board of Directors.

"With these funds, we are confident we have the resources to develop our immunoassay technology for use in the diagnostics field," said Philippe Goix, PhD, CEO of Singulex. "Already, the assays we have developed and optimized for our pharmaceutical partners have enabled them to see biomarker level differences in blood samples with and without drugs that they had not been able to see before, thus offering new insights for their clinical trials."

Singulex has closed partnerships with multiple large pharmaceutical companies to use Erenna technology and immunoassays to help them better understand the effects of their compounds early in preclinical studies and clinical trials. With its ability to detect and measure minute protein biomarker changes at very low levels, Singulex's technology also has significant potential for clinical applications in personalized medicine across multiple diseases.

Singulex will use the funds from this financing to deploy its product and services in the emerging molecular clinical diagnostic market. Initially, the company will focus on cardiovascular disease risk diagnostics using its assay platform for the biomarker c Troponin I (cTnI), a well-validated marker for cardiac necrosis.

"Singulex's steady progress in publishing strong data from premier medical schools in the country indicated that the Erenna technology can make significant contributions to the diagnostics field, specifically in the cardiovascular area but also across a wide range of diseases. This makes an attractive investment opportunity," noted Hozoji. "Not only that, but the potential for the Singulex technology to be used to determine which patients respond to specific drugs should position the company to be a leader in personalized medicine."

About Singulex

Singulex develops and commercializes innovative product and service solutions that enable disease understanding and management for life science researchers and clinicians. Utilizing proprietary quantitative single molecule detection technology, Singulex provides unique biomarker answers that offer unprecedented level of sensitivity and accuracy of specific protein biomarker levels in a variety of biological samples. Singulex technology is currently used by academic and molecular diagnostic partners to further develop the significant clinical utility that the Erenna(TM) Immunoassay System enables. To learn more about Singulex, please visit us at http://www.singulex.com.

    Contact:
    Carolyn Hawley
    Porter Novelli Life Sciences for Singulex
    619-849-5375
    chawley@pnlifesciences.com


'/>"/>
SOURCE Singulex, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Singulex Collaborates With Large Pharmaceutical Company in Erenna(TM) Technology Access Program
2. Karolinska Development Closes Fully Subscribed New Share Issue
3. Concentric Medical Closes on $15 Million Financing
4. Intradigm Closes Final Tranche of $21.4 Million Series B Financing
5. Diagnoplex Closes CHF10 Million ($8.3 Million) Series A Financing
6. AEterna Zentaris Closes Sale of Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners
7. MicroPhage Closes Latest Financing
8. Arete Therapeutics Closes $16.7 Million in Final Tranche of Its Series A Financing
9. CVBT Closes Clinical Development Agreement for Coronary Heart Disease Drug Candidate
10. Starfish Ventures Closes Australias Largest Venture Capital Fund With $185 Million Tech Fund
11. Valor Medical Closes $1.4 Million Convertible Debt and Receives ISO 13485 Certification
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... 16, 2017 Research and Markets ... Global Markets" report to their offering. ... ... biobrick parts, delivery plasmids, chassis organisms, synthetic cells, production ... genome editing, bioinformatics and specialty media) and enabled technologies ...
(Date:2/16/2017)... 16, 2017 Patient Care ... innovative telemedicine application, new and leading edge therapies ... a boom worldwide. The healthcare sector as whole ... services and new therapies for companies such as ... Cellectar Biosciences, Inc. (NASDAQ: CLRB ), ...
(Date:2/16/2017)... N.J. , Feb. 16, 2017  Champions Oncology, ... in the development and sale of advanced technology solutions ... oncology drugs, today announced the addition of new cohorts ... These new models will expand Champions, product line ... head and neck cancer, AML, and non-small cell lung ...
(Date:2/16/2017)... Feb. 16, 2017  Rhythm, a biopharmaceutical ... deficiencies that result in life-threatening metabolic disorders, ... million mezzanine round of financing with existing ... Capital, New Enterprise Associates, Pfizer Venture Investments, ... healthcare investment fund. Rhythm will use the ...
Breaking Biology Technology:
(Date:2/13/2017)... -- Former 9/11 Commission border counsel and Special Counsel ... of Identity Strategy Partners, LLP, today releases the ... Order: Protecting the Nation From Foreign Terrorist Entry Into ... President Trump,s ,Travel Ban, Executive Order gains more notoriety ... travel ban, it is important that our national discourse ...
(Date:2/8/2017)... 2017 Report Highlights ... The global synthetic-biology market reached nearly ... 2021, growing at a compound annual growth rate (CAGR) of ... the global markets for synthetic biology. - Analyses of global ... projections of compound annual growth rates (CAGRs) through 2021. - ...
(Date:2/7/2017)... York , February 7, 2017 ... ID Global Solutions Corporation [OTC: IDGS], ("Ipsidy" or the ... and electronic transaction processing services, is pleased to announce ... the Company. Effective January 31, 2017, ... Board of Directors, CEO and President.  An experienced payment ...
Breaking Biology News(10 mins):